Clinical trial · Observational
Psychometric Properties of the Therapy-Related Symptom Checklist-Children
Psychometric Properties of the Turkish Version of Therapy-Related Symptom Checklist for Children Scale
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diagnosis and treatment of childhood cancers is an exhausting process that affects both children and their caring parents physically and mentally. While the survival rate in childhood cancers was 28% in the 1960s, this rate has increased up to 80% with the developments in treatment methods. Although the main methods used in cancer treatment today are surgical treatment, radiotherapy, and immunotherapy, the main component of cancer treatment is chemotherapy. Improvements in chemotherapy protocols have increased survival; however, the use of high-dose chemotherapy may increase the frequency and severity of symptoms that may be seen in children. Therefore, diagnosis and management of treatment-related symptoms in the pediatric population receiving chemotherapy treatment as soon as possible is of vital importance as it will significantly affect the quality of life of children. In this context, this study aimed to add to the national literature by conducting a Turkish validity and reliability study of a checklist suitable for the use of health professionals in clinics for monitoring the side effects of chemotherapy. In the study, validity and reliability tests will be performed for intercultural scale adaptation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric ALL | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Pediatric Leukemia, Acute Myeloid | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TRSC-C | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Turkish version of the scale
- timeFrame
- April 2022-December 2024
- description
- Use of the Turkish version of the Theraphy Related Symptom Checklist. Min: 0, Max: 120 points The higher the score, the worse the symptoms.
Secondary outcomes (2)
- measure
- frequency of symptoms
- timeFrame
- April 2022-December 2024
- description
- frequency of symptoms related to chemotherapy treatment
- measure
- symptom severity
- timeFrame
- April 2022-December 2024
- description
- symptom severity due to chemotherapy treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patient is between 2-18 years of age * The patient has received chemotherapy treatment at least twice, * The patient/caregiver parent speaks Turkish and is open to communication * Volunteering to participate in the study. Exclusion Criteria: * The patient is younger than 2 years of age * The patient has never received chemotherapy * The subject/caregiver parent does not speak Turkish * The patient is being treated for a disease other than leukemia
References
Publications (0)
Data not yet available